PRODUCT LITERATURE

Non‑parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing

---

Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal
(IN) esketamine has been recently approved in several countries for treating depression. The clinical utility of these treatments
is limited by a paucity of publicly funded IV ketamine and IN esketamine programs and cost barriers to private treatment
programs, as well as the drug cost for IN esketamine itself, which makes generic ketamine alternatives an attractive option.
Though evidence is limited, use of non-parenteral racemic ketamine formulations (oral, sublingual, and IN) may offer more
realistic access in less rigidly supervised settings, both for acute and maintenance treatment in select cases. However, the psychiatric
literature has repeatedly cautioned on the addictive potential of ketamine and raised caution for both less supervised
and longer-term use of ketamine.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Ketamine
Non‑parenteral Ketamine
Depression

Specific Detail Info

CNS Drugs (2022) 36:239–251

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment